07:00 , Jul 2, 2012 |  BioCentury  |  Finance

3Q Financial Markets Preview: Avoiding burnout

A slew of milestones through year end combined with last quarter's outperformance have investors hopeful that the biotech sector can continue to fend off a dreary macroeconomic environment and weakness in the broader markets. Buysiders...
07:00 , Apr 2, 2012 |  BioCentury  |  Finance

Some like it hot

Despite signs the biotech rally is getting "toppy," market watchers ranging from buysiders to bankers to technical analysts think it can continue into this quarter. They say the market still has momentum and investors still...
07:00 , Apr 2, 2012 |  BioCentury  |  Finance

Thinking small again

Buysiders shied away from small and micro-cap stocks over the last few years as poor performance and inadequate financing plagued these groups. But many investors now see them as undervalued. These include winners from last...
08:00 , Jan 9, 2012 |  BioCentury  |  Finance

More knowledge, less fluff

More knowledge is usually considered a good thing. And in the past 20 years there has been an exponential increase in the amount of scientific and experiential knowledge that underpins the biopharmaceutical industry. But knowledge...
08:00 , Jan 9, 2012 |  BioCentury  |  Finance

PDUFAs produce yawns

Stephen Hansen Senior Writer  There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest...
07:00 , Oct 3, 2011 |  BioCentury  |  Finance

Cost averaging down

Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead...
07:00 , Oct 3, 2011 |  BioCentury  |  Finance

Launches stratified

The dramatic change in sales projections for Provenge sipuleucel-T from Dendreon Corp. on Aug. 2 was a watershed moment for biotech launch stories. Going into 4Q, some investors are still sorting out their bets on...
07:00 , Aug 15, 2011 |  BioCentury  |  Finance

Rebalancing act

Companies in the midst of launching products or with weak balance sheets have been sold off or avoided by most investors during the market roller-coaster of the past two weeks. However, a handful of companies...
07:00 , Jul 4, 2011 |  BioCentury  |  Finance

3Q Financial Markets Preview: Hoping the rally has legs

Buysiders expect biotech may be able to continue to outperform the broader markets, despite a retreat from spring highs. In particular, they see two bright spots for the sector: selective gains on a full calendar...
07:00 , Jul 4, 2011 |  BioCentury  |  Finance

3Q Financial Markets Preview: Flavored with Phase III

The upcoming clinical and regulatory calendar isn't as densely packed as it was in the first half. But biotech investors are looking especially to Phase III data across all market cap segments through year end....